Physician profile
Thomas P Peller
NPI 1497715726
$2,412.81
in general payments reported to CMS, 2019-2025
24 companies · $836 in 2025
The $836 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $74.54 · 2021: $71.93 · 2022: $253 · 2023: $424 · 2024: $549 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767 · Education: $41.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.16 |
| Education | $41.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $610.59 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $548.52 | 2019-2025 | |
| Genzyme Corporation | $351.87 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $171.26 | 2023-2025 | Dupixent |
| Novo Nordisk INC | $104.60 | 2019-2025 | Rybelsus, Wegovy |
| Lilly USA, LLC | $86.90 | 2020-2025 | Omvoh |
| Pfizer INC. | $71.79 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $68.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $48.22 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $47.96 | 2020-2024 | Vaxelis, Vaxneuvance, Rotateq |
| Exact Sciences Corporation | $44.69 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.71 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $33.59 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $29.60 | 2025 | |
| Nestle Healthcare Nutrition INC. | $23.87 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $22.76 | 2025 | Entyvio |
| Astrazeneca Pharmaceuticals Lp | $19.23 | 2020 | |
| Mylan Specialty L.P. | $14.49 | 2024 | Yupelri |
| Intercept Pharmaceuticals, INC. | $14.47 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.09 | 2023 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $12.98 | 2020 | |
| Allergan, INC. | $11.95 | 2019 | |
| Ucb, INC. | $11.49 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Peller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.